Literature DB >> 3658362

Anterior ischemic optic neuropathy. VII. Incidence of bilaterality and various influencing factors.

M Beri1, M R Klugman, J A Kohler, S S Hayreh.   

Abstract

A prospective study was conducted in 438 patients with anterior ischemic optic neuropathy (AION). There were 388 patients with nonarteritic AION and 50 with arteritic AION. The risk of bilaterality in patients with arteritic AION was found to be 1.9 times the risk in patients with nonarteritic AION (P = 0.0118). The cumulative incidence curve, considering the time taken to develop bilateral AION for nonarteritic cases was significantly (P = 0.0103) different from that for arteritic cases. The estimated 25th-percentile time to development of bilateral AION was much shorter in patients with arteritic AION (0.4 month) than in those with nonarteritic AION (32.4 months). In arteritic AION, unilateral as well as bilateral AION had almost invariably developed before systemic steroid therapy was started and not after, indicating that this therapy is effective in preventing the development of AION in giant cell arteritis. In nonarteritic AION, the risk of bilaterality was significantly greater in men (P = 0.0113) and in young (less than 45 years old) patients with diabetes (P = 0.0245), with no significant difference attributable to the other age groups or other associated systemic diseases. In this study, it was found that young diabetic men have a risk of AION developing in the second eye that is 1.56 times the risk in young diabetic women, 2.56 times the risk in women who either are nondiabetic or are not young, and 1.64 times the risk in both older men and nondiabetic men.

Entities:  

Mesh:

Year:  1987        PMID: 3658362     DOI: 10.1016/s0161-6420(87)33350-0

Source DB:  PubMed          Journal:  Ophthalmology        ISSN: 0161-6420            Impact factor:   12.079


  40 in total

1.  Temporal artery biopsy in the management of giant cell arteritis with neuro-ophthalmic complications.

Authors:  P Riordan-Eva; K Landau; J O'Day
Journal:  Br J Ophthalmol       Date:  2001-10       Impact factor: 4.638

2.  The natural history of non-arteritic anterior ischaemic optic neuropathy.

Authors:  G V Sawle; C B James; R W Russell
Journal:  J Neurol Neurosurg Psychiatry       Date:  1990-10       Impact factor: 10.154

3.  Recurrent herpes labialis as a potential risk factor for nonarteritic anterior ischemic optic neuropathy.

Authors:  L N Johnson; G B Krohel; S D Allen; R Mozayeni
Journal:  J Natl Med Assoc       Date:  1996-06       Impact factor: 1.798

4.  Non-arteritic anterior ischaemic optic neuropathy and cataract surgery.

Authors:  John Elston
Journal:  Br J Ophthalmol       Date:  2007-05       Impact factor: 4.638

5.  Effects of L-arginine on anatomical and electrophysiological deterioration of the eye in a rodent model of nonarteritic ischemic optic neuropathy.

Authors:  Hideki Chuman; Tomoyuki Maekubo; Takako Osako; Michitaka Ishiai; Naoko Kawano; Nobuhisa Nao-I
Journal:  Jpn J Ophthalmol       Date:  2013-05-29       Impact factor: 2.447

6.  Treatment of polymyalgia rheumatica and giant cell arteritis.

Authors:  M T Watts; M E Nelson; I G Rennie
Journal:  Ann Rheum Dis       Date:  1990-07       Impact factor: 19.103

7.  [Episodic progressive bilateral visual deterioration].

Authors:  S Heinzelmann; F Staubach; W A Lagrèze
Journal:  Ophthalmologe       Date:  2008-11       Impact factor: 1.059

8.  Intravitreal triamcinolone injections in non-arteritic anterior ischemic optic neuropathy.

Authors:  Corina Radoi; Tony Garcia; Catherine Brugniart; Alain Ducasse; Carl Arndt
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2013-11-01       Impact factor: 3.117

9.  Role of retinal hypoxia in diabetic macular edema: a new concept.

Authors:  Sohan Singh Hayreh
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2007-09-18       Impact factor: 3.117

10.  Increased level of platelet P-selectin in nonarteritic anterior ischemic optic neuropathy.

Authors:  Valeria Nagy; Bence Kolozsvari; Zsuzsa Balogh; Adrienne Csutak; Marta Kasza; Bela Nagy; Laszlo Kardos; Andras Berta; Gyorgy Pfliegler
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2012-11-16       Impact factor: 3.117

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.